Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

AltaRex updates OvaRex MAb and BrevaRex MAb clinical progress

March 29, 1999

Maxim allowed additional U.S. patent for Maxamine technology

March 22, 1999

Mouse study provides preliminary indications of the antitumor efficacy of AR-209

March 18, 1999

Clinical trials of needle-free delivery of DNA vaccine begin

March 18, 1999

Second prostate cancer study initiated with Multikine

March 16, 1999

Genzyme Molecular Oncology initiates clinical trials of combined-antigen melanoma vaccine

March 10, 1999

Techniclone to present clinical data on newly designated orphan drug at ASCO

March 10, 1999

Betathine approved for accelerated phase I/II trials in Canada

March 2, 1999

ImmunoGen discusses progress of tumor-activated prodrugs

March 2, 1999

Medarex reacquires worldwide rights to MDX-210

March 1, 1999

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.